We can't find the internet
Attempting to reconnect
18026.1 PFLS-LS
Type 3 Pharma - Therapie von Krebs mit genetisch modifizierten Bakterien
Résumé
Type 3 Pharma - Therapie von Krebs mit genetisch modifizierten Bakterien
Textes supplémentaires
Abstract
Bacteria offer an ideal vehicle to deliver cargo to cancer cells as they preferentially grow within solid tumors.|We have developed a technology based on a bacterial nano-needle to directly inject proteins into cancer cells|and have obtained very promising results in delivering toxic proteins to cancer cells. Our aim is to optimize this|system and to validate its efficacy in murine models of cancer. Our vision is to bring this novel treatment|strategy into clinicial practice.
Participants
Christoph Kasper
Wirtschaftspartner
ch.kasper@t3pharma.com
T3 Pharmaceuticals GmbH Christoph Kasper Klingelbergstr. 50/70 4056 Basel BS CH
Erich Nigg
Kontaktperson
erich.nigg@unibas.ch
Universität Basel Biozentrum Erich Nigg Spitalstrasse 41 4056 Basel BS CH
Détails du projet
- Office de recherche
- INNOSUISSE
- Statut du projet
- Abgeschlossen
- Type de projet
- Forschungsprojekt
- Date de début
- 2015-08-31
- Date de fin
- 2017-08-31
- Coûts totaux approuvés
- CHF 235456.00
- Section
- 20 Förderbereich Life Sciences
- Domaine politique NABS
- Industrielle Produktivität und Technologie
Disciplines de recherche
- T490 Biotechnology 100.0%